Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy

被引：2
|
作者：
Qian, Hu [1 ,2 ]
Yang, Xingcheng [1 ,2 ]
Zhang, Tingting [3 ,4 ,5 ]
Zou, Ping [6 ]
Zhang, Yicheng [1 ,2 ]
Tian, Weiwei [4 ,5 ]
Mao, Zekai [1 ,2 ,8 ]
Wei, Jia [1 ,2 ,4 ,5 ,7 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Immunotherapy Res Ctr Hematol Dis Hubei Prov, Wuhan, Peoples R China
[3] Third Hosp Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Canc Ctr, Taiyuan, Peoples R China
[4] Third Hosp Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Dept Hematol, Taiyuan, Peoples R China
[5] Shanxi Bethune Hosp, Shanxi Acad Med Sci, Sino German Joint Oncol Res Lab, Taiyuan, Shanxi, Peoples R China
[6] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China
[7] Third Hosp Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Dept Hematol, Taiyuan 030032, Shanxi, Peoples R China
[8] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 04期
基金：
中国国家自然科学基金;
关键词：
TIXAGEVIMAB-CILGAVIMAB; IMMUNE RECONSTITUTION; CLINICAL-ASPECTS; CHILDREN; RECOMMENDATIONS; MANAGEMENT; LEUKEMIA; DISEASE; MALIGNANCIES; ASSOCIATION;
D O I：
10.1002/ajh.27198
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chimeric antigen receptor (CAR) T-cell therapy, an innovative immunotherapeutic against relapsed/refractory B-cell lymphoma, faces challenges due to frequent viral infections. Despite this, a comprehensive review addressing risk assessment, surveillance, and treatment management is notably absent. This review elucidates immune response compromises during viral infections in CAR-T recipients, collates susceptibility risk factors, and deliberates on preventive strategies. In the post-pandemic era, marked by the Omicron variant, new and severe threats to CAR-T therapy emerge, necessitating exploration of preventive and treatment measures for COVID-19. Overall, the review provides recommendations for viral infection prophylaxis and management, enhancing CAR-T product safety and recipient survival. Risk factors and prevention recommendations for viral infections in CAR T-cell therapy.image
引用
收藏
页码：662 / 678
页数：17
相关论文
共 50 条
  • [1] Clinical phenotypes of CAR-T-cell related hematotoxicity in relapsed/refractory large B-cell lymphoma
    Rejeski, K.
    Sesques, P.
    Berger, C.
    Jentzsch, L.
    Mougiakakos, D.
    Froelich, L.
    Bucklein, V
    Blumenberg, V
    Schmidt, C.
    Jallades, L.
    Fehse, B.
    Faul, C.
    Weigert, O.
    Dreyling, M.
    von Bergwelt-Baildon, M.
    Mackensen, A.
    Bethge, W.
    Ayuk, F.
    Bachy, E.
    Salles, G.
    Subklewe, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 45 - 46
  • [2] Dynamic imaging for CAR-T-cell therapy
    Emami-Shahri, Nia
    Papa, Sophie
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2016, 44 : 386 - 390
  • [3] Prevention of CAR-T-cell dysfunction
    LaFleur, Martin W.
    Miller, Brian C.
    Sharpe, Arlene H.
    [J]. NATURE BIOMEDICAL ENGINEERING, 2020, 4 (01) : 16 - 17
  • [4] Prevention of CAR-T-cell dysfunction
    Martin W. LaFleur
    Brian C. Miller
    Arlene H. Sharpe
    [J]. Nature Biomedical Engineering, 2020, 4 : 16 - 17
  • [5] Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt's Lymphoma
    Kenkel, Troy J.
    Sridhar, Nithya
    Hammons, Lindsay R.
    Hintzke, Maria
    Shah, Nirav N.
    [J]. MEDICAL SCIENCES, 2023, 11 (04)
  • [6] Advances in CAR-T-cell therapy in T-cell malignancies
    Zheng, Rubing
    Zhu, Xiaojian
    Xiao, Yi
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [7] outlook A solid start for CAR-T-cell therapy
    Dolgin, Elie
    [J]. NATURE, 2022, 612 (7941) : S50 - S52
  • [8] CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
    Mishra, Abhinava K.
    Gupta, Ashna
    Dagar, Gunjan
    Das, Dayasagar
    Chakraborty, Abhijit
    Haque, Shabirul
    Prasad, Chandra Prakash
    Singh, Archana
    Bhat, Ajaz A.
    Macha, Muzafar A.
    Benali, Moez
    Saini, Kamal S.
    Previs, Rebecca Ann
    Saini, Deepak
    Saha, Dwaipayan
    Dutta, Preyangsee
    Bhatnagar, Aseem Rai
    Darswal, Mrinalini
    Shankar, Abhishek
    Singh, Mayank
    [J]. VACCINES, 2023, 11 (11)
  • [9] T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it
    Yin, Xuechen
    He, Lingfeng
    Guo, Zhigang
    [J]. IMMUNOLOGY, 2023, 169 (04) : 400 - 411
  • [10] Current progress of CAR-T-cell therapy for patients with multiple myeloma
    Nakashima, Takahiro
    Kagoya, Yuki
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (01) : 15 - 22
12345